Biochemical Engineering

Lonza and ABL Bio Collaborate on Bispecific Antibody Product

Lonza and ABL Bio Collaborate on Bispecific Antibody Product

7th April 2023

Lonza announced on April 4, 2023 an agreement with ABL Bio, a Korean biologics company with a focus on bispecific antibodies for immune-oncology and neurodegenerative diseases. The collaboration agreement between the two companies supports the development and manufacturing of ABL Bio’s new bispecific antibody product.  Source: Biopharm International 7/4/2023


Back to group news